Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JIA RUAN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1376623926
CMS profile
108034
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,991.97

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $1,980.00 1
Education $11.97 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Kite Pharma, Inc. $1,980.00 1
Acrotech Biopharma LLC $11.97 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JIA RUAN

NPI 1376623926 · CMS profile ID 108034

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1376623926?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JIA RUAN, NPI 1376623926, CMS profile ID 108034. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376623926?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JIA RUAN, NPI 1376623926, CMS profile ID 108034. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376623926?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JIA RUAN, NPI 1376623926, CMS profile ID 108034, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1376623926?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $1,991.97 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Kite Pharma, Inc. $1,980.0006/11/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844420977 CMS
Acrotech Biopharma LLC $11.9703/25/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855382275 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $14,128.30 15
PY2020 $7,040.00 4
PY2021 $1,991.97 2
PY2022 $5,755.00 3
PY2023 $11,213.34 12
PY2024 $10,752.26 8
PY2025 $4,100.00 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,546,590.26 78
PY2024 Principal investigator $1,600,965.60 22
PY2023 Principal investigator $3,194,241.54 18
PY2022 Principal investigator $5,482,463.47 22
PY2021 Principal investigator $3,970,415.27 4
PY2020 Principal investigator $2,060,376.66 28
PY2019 Principal investigator $1,935,439.19 27

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

27 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $143,412.76 11/04/2019 Non-covered Recipient Entity
Weill Cornell Med College
A Multicenter Phase 2 Study of Acalabrutinb, Lenalidomide, Rituximab with Real Time MRD Monitoring in Patients with Previous Untreated MCL No dispute reported 06/30/2026 685623943
Principal investigator 1 Celgene Corporation $389.76 10/21/2019 Non-covered Recipient Entity
Weill Cornell Medical College
A Multiple-center Phase 2 Study of Acalabrutinib-Lenalidomide-Rituximab in Patients with Previous Untreated Mantle Cell Lymphoma (RV-CL-MCL-PI-13239) No dispute reported 06/30/2026 675419945
Principal investigator 1 Seattle Genetics, Inc. $778.05 10/21/2019 Non-covered Recipient Entity
WEILL CORNELL MEDICAL COLLEGE
A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP ACHP versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas No dispute reported 06/30/2026 678824755
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $11,174.99 10/17/2019 Non-covered Recipient Entity
Weill Medical College Of Cornell University
PCYC-1123-CA No dispute reported 06/30/2026 673090665
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $7,461.30 10/17/2019 Non-covered Recipient Entity
Weill Medical College Of Cornell University
PCYC-1123-CA No dispute reported 06/30/2026 673090671
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $5,980.34 10/17/2019 Non-covered Recipient Entity
Weill Medical College Of Cornell University
PCYC-1123-CA No dispute reported 06/30/2026 673090727
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $14,176.47 10/17/2019 Non-covered Recipient Entity
Weill Medical College Of Cornell University
PCYC-1123-CA No dispute reported 06/30/2026 673090734
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $2,984.52 10/17/2019 Non-covered Recipient Entity
Weill Medical College Of Cornell University
PCYC-1123-CA No dispute reported 06/30/2026 673090759
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,434,528.00 10/01/2019 Non-covered Recipient Entity
Weill Med College Of Cornell
A Multicenter Phase 2 Study of Acalabrutinb, Lenalidomide, Rituximab with Real Time MRD Monitoring in Patients with Previous Untreated MCL No dispute reported 06/30/2026 685624021
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $3,750.00 09/24/2019 Non-covered Recipient Entity
Weill Medical College Of Cornell University
PCYC-1123-CA No dispute reported 06/30/2026 673090623
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $4,568.55 09/24/2019 Non-covered Recipient Entity
Weill Medical College Of Cornell University
PCYC-1123-CA No dispute reported 06/30/2026 673090629
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 08/12/2019 Non-covered Recipient Entity
WEILL CORNELL MEDICAL COLLEGE
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 654265541
Principal investigator 1 Janssen Research & Development, LLC $2,946.00 08/05/2019 Non-covered Recipient Entity
WEILL CORNELL MEDICAL COLLEGE
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 654265539
Principal investigator 1 Janssen Research & Development, LLC $1,685.00 07/29/2019 Non-covered Recipient Entity
WEILL CORNELL MEDICAL COLLEGE
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 654265533
Principal investigator 1 Seattle Genetics, Inc. $1,044.05 07/16/2019 Non-covered Recipient Entity
WEILL CORNELL MEDICAL COLLEGE
A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP ACHP versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas No dispute reported 06/30/2026 678824747
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 07/15/2019 Non-covered Recipient Entity
WEILL CORNELL MEDICAL COLLEGE
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 654265531
Principal investigator 1 Janssen Research & Development, LLC $4,715.00 06/13/2019 Non-covered Recipient Entity
WEILL CORNELL MEDICAL COLLEGE
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 654265529
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $10,374.00 06/06/2019 Non-covered Recipient Entity
Weill Medical College Of Cornell University
PCYC-1123-CA No dispute reported 06/30/2026 673090523
Principal investigator 1 Celgene Corporation $18,604.00 05/15/2019 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase 1/2, Open-label, Multi-center Study to Assess the Safety and Tolerability of Durvalumab (Anti-PDL1 Antibody) as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocitic Leukemia (MEDI4736-NHL-001) No dispute reported 06/30/2026 675419965
Principal investigator 1 Seattle Genetics, Inc. $2,467.15 04/18/2019 Non-covered Recipient Entity
WEILL CORNELL MEDICAL COLLEGE
A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP ACHP versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas No dispute reported 06/30/2026 678824671
Principal investigator 1 Celgene Corporation $242,691.75 04/04/2019 Non-covered Recipient Entity
Weill Cornell Medical Center
Phase II Study of CC486-CHOP for Previously Untreated Peripheral T-cell Lymphoma (OA-CL-PTCL-PI-13043) No dispute reported 06/30/2026 675419979
Principal investigator 1 Seattle Genetics, Inc. $5,166.85 04/03/2019 Non-covered Recipient Entity
WEILL CORNELL MEDICAL COLLEGE
A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP ACHP versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas No dispute reported 06/30/2026 678824661
Principal investigator 1 Seattle Genetics, Inc. $2,500.00 03/27/2019 Non-covered Recipient Entity
WEILL CORNELL MEDICAL COLLEGE
A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP ACHP versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas No dispute reported 06/30/2026 678824663
Principal investigator 1 Celgene Corporation $8,010.00 02/13/2019 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
A Phase Ib multicenter, open-label study to determine the recommended dose and regimen of durvalumab in combination with lenalidomide with and without low-dose dexamethasone in subjects with newly diagnosed multiple myeloma (MEDl-4736-NHL-001) No dispute reported 06/30/2026 675419967
Principal investigator 1 Seattle Genetics, Inc. $1,000.00 01/16/2019 Non-covered Recipient Entity
WEILL CORNELL MEDICAL COLLEGE
A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP ACHP versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas No dispute reported 06/30/2026 678824659
Principal investigator 1 Acerta Pharma LLC $1,000.00 01/12/2019 Non-covered Recipient Entity
Weill Med College Of Cornell
An Open label Phase 1b Study of ACP196 in Subjects with Relapsed or Refractory de Novo Activated B-cell ABC Subtype of Diffuse Large BCell Lymphoma No dispute reported 06/30/2026 685622629
Principal investigator 1 Celgene Corporation $530.65 01/02/2019 Non-covered Recipient Entity
NEW YORKPRESBYTERIAN-COLUMBIA UNIV MEDICAL CTR
Phase II Study of Lenalidomide plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma (RV-MCL-PI-0612) No dispute reported 06/30/2026 675418131